Anticardiolipin antibodies and mortality in patients with ischemic stroke: A prospective follow-up study

Neuroepidemiology

Volumn 21, Issue 2, 2002, Pages 93-99

  Tanne, David ^d,e   D'Olhaberriague, Luis ^c   Trivedi, Ashish M ^b   Salowich Palm, Leeza ^b   Schultz, Lonni R ^b   Levine, Steven R ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c Neurosciences Fujisawa Research Institute of America   (United States)

^d TEL AVIV UNIVERSITY   (Israel)

^e SHEBA MEDICAL CENTER   (Israel)

Author keywords

Anticardiolipin antibodies; Mortality; Stroke

Indexed keywords

CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G;

ADULT; AGED; ARTERY OCCLUSION; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROSPECTIVE STUDY; RISK FACTOR; THROMBOSIS;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTICARDIOLIPIN; BIOLOGICAL MARKERS; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 0036126596     PISSN: 02515350     EISSN: None     Source Type: Journal    
DOI: 10.1159/000048623     Document Type: Article

References (37)

1. The antiphospholipid syndrome: Ten years on
2. Antiphospholipid-protein antibodies. Clinical use of laboratory test results (identification, predictive value, treatment)
3. Epidemiology of antiphospholipid antibodies and vascular disease
4. Anticardiolipin antibodies are an independent risk factor for first ischemic stroke
5. Anticardiolipin antibodies in acute non-hemorrhagic stroke seen within six hours after onset
6. The anticardiolipin antibody in elderly stroke patients: Its effect on stroke types, recurrence, and the coagulation-fibrinolysis system
7. Anticardiolipin antibodies are an independent risk factor for ischemic stroke
8. Elevated anticardiolipin antibody titer is a stroke risk factor in a multiethnic population independent of isotype or degree of positivity
9. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis
10. Anticardiolipin antibodies in an unselected stroke population
11. The frequency of antiphospholipid antibodies in an unselected stroke population
12. Anticardiolipin antibodies are not an independent risk factor for stroke: An incident case-referent study nested within the MONICA and Vasterbotten cohort project
13. A prospective epidemiological study on the occurrence of antiphospholipid antibody: The Montpellier antiphospholipid study
14. Anticardiolipin antibodies and their associations with cerebrovascular risk factors
15. The 1982 revised criteria for the classification of systemic lupus erythematosus
16. Special report
17. Anticardiolipin antibodies and the risk of recurrent thrombo-occlusive events and death
18. Antibodies to cardiolipin in stroke: Association with mortality and functional recovery in patients without systemic lupus erythematosus
19. Association between anticardiolipin antibodies and mortality in patients with peripheral arterial disease
20. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: A 4-year prospective study from the Italian registry
21. IgG anticardiolipin antibody titer > 40 GPL and the risk of subsequent thrombo-occlusive events and death: A prospective cohort study
22. Anticardiolipin antibodies: Clinical consequences of 'low titers'
23. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an international workshop
24. The feasibility of a collaborative double-blind study using an anticoagulant: The Warfarin-Aspirin Recurrent Stroke Study (WARSS), the Antiphospholipid Antibodies and Stroke Study (APASS), the Patent Foramen Ovale in Cryptogenic Stroke Study (PICSS), and the Hemostatic System Activation Study (HAS)
25. Autoantibodies in patients with carcinoma of the breast. Correlation with prognosis
26. Incidence of autoantibodies in cancer patients
27. Antiphospholipid antibodies and malignancies
28. Anticardiolipin and antinuclear antibodies in cancer patients - A case control study
29. Anticardiolipin antibodies in acute myeloid leukemia: Prevalence and clinical significance
30. Autoantibodies against cardiolipin in the serum of patients with colorectal carcinoma: Their prognostic significance
31. Serum cardiolipin antibodies in cancer patients with thromboembolic events
32. β2-Glyco-protein I: Target antigen for autoantibodies in the 'antiphospholipid syndrome'
33. Antiphospholipid-protein antibodies and ischemic stroke: Not just cardiolipin any more
34. From antiphospholipid syndrome to antibody-mediated thrombosis
35. The use of an anti-β2-glycoprotein I assay for discrimination between anticardiolipin antibodies associated with infection and increased risk for thrombosis
36. Infarctlike lesions in the brain: Prevalence and anatomic characteristics at MR imaging of the elderly - Data from the Cardiovascular Health Study